shanghai and wilmington, delaware – april 23, 2020 -- hansoh pharmaceutical group company limited (“hansoh pharma”), a leading biopharmaceutical company in china, and nikang therapeutics, inc. (“nikang”), a u.s.-based early stage biotech company focused on discovering and developing innovative small molecule medicines to help patients with unmet medical needs, today announced a collaboration focused on development and commercialization of nkt-1992 – a small molecule in preclinical development – for viral infection in china, taiwan, hong kong, and macau (“greater china”).
discovered through structure-based design, nkt-1992 targets a highly conserved enzymatic domain that is critical for viral transcription and replication. inhibition of this mechanism of action can potentially achieve faster reduction of viral load and associated signs and symptoms.
for more information about the collaboration, please refer to
about hansoh pharmaceutical group company limited
hansoh pharma (3692:hk), a leading biopharmaceutical company in china, is committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders. hansoh pharma has over 9,000 dedicated employees in china and the united states.
founded in 1995, hansoh has fully integrated research and development, manufacturing, and commercial capabilities, supporting a leadership position in oncology, central nervous system (cns) disorders, infectious diseases, gastrointestinal disorders, diabetes, and autoimmune diseases, among others. with 1,200 professionals across r&d, hansoh has developed several internally discovered drug candidates into nmpa-approved innovative medicines including morinidazole (迈灵达®), a third-generation nitroimidazole antibiotic; peg-loxenatide (孚来美®), the first once-weekly long-acting glp-1 analogue discovered and developed in china for the treatment of diabetes; flumatinib (昕福®), a second-generation bcr-abl inhibitor for frontline treatment of chronic myeloid leukemia (cml); and almonertinib (阿美乐®), a third-generation egfr inhibitor for the treatment of nsclc.
about nikang therapeutics, inc.
nikang therapeutics, headquartered in wilmington, de, usa, is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. nikang’s target selection is driven by deep insights into disease biology and molecular pathways. nikang’s discovery approach is informed by target structure biology and capitalizes on structure-based drug design. the successful implementation of this strategy enables nikang to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. nikang strives to bring transformative medicines to patients in need.
for more information, please visit